Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
January 10, 2022 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD
December 15, 2021 08:30 ET
|
Skye Bioscience, Inc.
Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer SAN DIEGO, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the...
Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360
October 21, 2021 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program
October 12, 2021 13:35 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development
October 07, 2021 09:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases...
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer
October 05, 2021 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases...
Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering
September 29, 2021 16:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Announces $7.0 Million Registered Direct Offering
September 27, 2021 09:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360
September 21, 2021 09:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases...